ABSTRACT
T-cell prolymphocytic leukemia (T-PLL) is a rare mature T cell leukemia with aggressive clinical course, poor response to conventional therapies and high mortality rates. Classical cytogenetics and various genetic techniques have observed complex karyotypes and associated genes involved in the molecular pathogenesis of T-PLL, among which the proto-oncogene T-cell leukemia/lymphoma 1 (TCL1) as a hallmark of malignancy is hyper-activated and abnormally expressed in many T-PLL cases. Progress has been made to identify the presence of chromosomal rearrangements and subsequent changes in key molecular pathways typically involving Akt, which may hint cytogenetic mechanisms underlying the pathogenesis of T-PLL and indicate new treatment targets. In this article, we describe current insights of T-PLL with an emphasis on the potential role of TCL1 gene disorders and TCL1-Akt interactions in cell transformation and disease progression, followed by discussion on current treatment options and novel therapeutic approaches based on cytogenetics, which still remains to be explored for the effective management of T-PLL and other TCL1-driven hematological malignancies.
Subject(s)
Disease Susceptibility , Leukemia, Prolymphocytic, T-Cell/etiology , Proto-Oncogene Proteins/genetics , Animals , Biomarkers, Tumor , Combined Modality Therapy , Cytogenetic Analysis , Disease Management , Humans , Immunohistochemistry , Leukemia, Prolymphocytic, T-Cell/diagnosis , Leukemia, Prolymphocytic, T-Cell/metabolism , Leukemia, Prolymphocytic, T-Cell/surgery , Models, Biological , Multigene Family , Proto-Oncogene Mas , Proto-Oncogene Proteins/metabolism , Translocation, Genetic , Treatment OutcomeABSTRACT
T-cell prolymphocytic leukaemia (T-PLL) is an extremely uncommon haematological malignancy that has an aggressive course and a grave prognosis. We describe a patient who presented with lymphocytosis, scalp erythema, ascites and splenomegaly and was diagnosed with T-PLL. He was treated with alemtuzumab with a good response and was referred for allogeneic stem cell transplantation.
Subject(s)
Antibodies, Monoclonal, Humanized/therapeutic use , Antineoplastic Agents/therapeutic use , Leukemia, Prolymphocytic, T-Cell , Rare Diseases , Stem Cell Transplantation , Alemtuzumab , Antigens, CD , Antigens, Neoplasm , CD52 Antigen , Glycoproteins , Humans , Leukemia, Prolymphocytic, T-Cell/diagnosis , Leukemia, Prolymphocytic, T-Cell/drug therapy , Leukemia, Prolymphocytic, T-Cell/surgery , Male , Middle Aged , PrognosisSubject(s)
Adenovirus Infections, Human/complications , Catatonia/drug therapy , Hypnotics and Sedatives/therapeutic use , Limbic Encephalitis/complications , Propofol/therapeutic use , Adenovirus Infections, Human/cerebrospinal fluid , Adenovirus Infections, Human/diagnosis , Anxiety Disorders/complications , Benzodiazepines/therapeutic use , Bone Marrow Transplantation , Catatonia/diagnosis , Catatonia/virology , Diagnosis, Differential , Fatal Outcome , Female , Herpesvirus 6, Human/isolation & purification , Humans , Hypnotics and Sedatives/pharmacology , Immunocompromised Host , Leukemia, Prolymphocytic, T-Cell/immunology , Leukemia, Prolymphocytic, T-Cell/surgery , Limbic Encephalitis/diagnosis , Limbic Encephalitis/virology , Middle Aged , Propofol/pharmacology , Psychomotor Agitation/diagnosis , Tacrolimus/bloodABSTRACT
Malakoplakia is a disease especially of the urinary tract with typical plaques most frequently observed in the urinary bladder's mucosa. In the context of immunosuppression malakoplakia can also occur in other organs. Some of these extravesical malakoplakias are associated with an infection by Rhodococcus equi, a rare human pathogen well known from veterinary medicine. Here we present the first case of a pleural malakoplakia without lung involvement caused by a proved Rhodococcus equi infection.
Subject(s)
Actinomycetales Infections/microbiology , Leukemia, Prolymphocytic, T-Cell/surgery , Malacoplakia/microbiology , Pleural Diseases/microbiology , Rhodococcus equi/isolation & purification , Stem Cell Transplantation/adverse effects , Actinomycetales Infections/complications , Actinomycetales Infections/surgery , Biopsy , Humans , Immunohistochemistry , Immunosuppressive Agents/adverse effects , Malacoplakia/surgery , Male , Middle Aged , Pleural Diseases/surgery , Tomography, X-Ray Computed , Transplantation, Homologous , Treatment OutcomeABSTRACT
T-prolymphocytic leukemia (T-PLL) has a very poor prognosis with conventional immunochemotherapy. Incidental reports suggest that allogeneic hematopoietic stem cell transplantation (allo-HSCT) might have a role in this disease. Therefore, the purpose of the present study was to analyze the outcome of transplants for T-PLL registered with the European Group for Blood and Marrow Transplantation database and the Royal Marsden Consortium. Eligible were 41 patients with a median age of 51 (24-71) years; median time from diagnosis to treatment was 12 months, and in complete remission (CR) (11), partial remission (PR) (12), stable or progressive disease (13) and unknown in 5 patients. A total of 13 patients (31%) received reduced-intensity conditioning. Donors were HLA-identical siblings in 21 patients, matched unrelated donors in 20 patients. With a median follow-up of surviving patients of 36 months, 3-year relapse-free survival (RFS) and OS was 19% (95% CI, 6-31%) and 21% (95% CI, 7-34%), respectively. Multivariate analysis identified TBI and a short interval between diagnosis and HSCT as factors associated with favorable RFS. Three-year non relapse mortality and relapse incidence were each 41% with the majority of relapses occurring within the first year. These data indicate that allo-HSCT may provide effective disease control in selected patients with T-PLL.